The Company, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.
The Company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The Company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.
HISTORY
2017 - The Company is a holding company incorporated in British Virgin Islands on July 4, 2017. The Company is headquartered in Taizhou, China.
- On July 21, 2017, the Company wholly owned subsidiary China SXT Group Limited (“SXT HK”) was incorporated in Hong Kong.
2019 On January 3, 2019, The Company s ordinary shares commenced trading on the Nasdaq Capital Market under the symbol of “SXTC.”
总部
178 Taidong Rd North
台州; 浙江;
邮编: 225300
联系方式: 购买China Sxt Pharmaceuticals Inc.报告以查看信息。
EMIS公司简介是一个更大的信息服务的一部分,它结合了公司,行业和国家数据和分析在超过125个新兴市场.
请求EMIS服务的演示查看更多信息, 申请试用